News

EU awards CE mark approval to EBX 041 SARS CoV2 diagnostic test for Coronavirus.- Eurobio Scientific

Read time: 1 mins

Published:26th Mar 2020

Eurobio Scientific announced CE mark approval for its EBX 041 SARS CoV2 proprietary test, developed specifically for the clinical diagnosis of COVID-19. The EBX 041 SARS CoV2 proprietary kit follows the design recommended by the French National Reference Center (CNR) and has been approved based on clinical samples with an independent hospital. This is a multiplex kit with three targets: two for identifying the virus and one target for a control integrated into each patient test.Comment: This is a multiplexed real-time PCR test that can be used directly on a large number of open thermal cycler instruments, present in diagnostic laboratories. After extraction, it makes it possible to rapidly detect (1h15) the genes identifying the SARS COv2 virus, as recommended by the World Health Organization (WHO).

Condition: Coronavirus/COVID-19 Infection

Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

FDA issues emergency use authorisation of Pemgarda (pemivibart) (formerly VYD 222) for pre-exposure prophylaxis of COVID 19,- Invivyd Inc.

Invivyd, Inc. a biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, announced that Pemgarda (pemivibart), formerly VYD 222, a half-life extended monoclonal antibody (mAb), has received emergency use authorization (EUA) from the FDA for the pre-exposure prophylaxis (prevention) of COVID-19 in adults and adolescents (12 years of age and older weighing at least 40 kg) who have moderate-to-severe immune compromise due to certain medical conditions or receipt of certain immunosuppressive medications or treatments and are unlikely to mount an adequate immune response to COVID-19 vaccination.

3 mins

Drug news

New data from three real-world retrospective studies of Veklury (remdesivir) are presented at the 31st Conference on Retroviruses and Opportunistic Infections (CROI)

Gilead Sciences, Inc. announced new data from three real-world retrospective studies being presented at the 31st Conference on Retroviruses and Opportunistic Infections (CROI)

2 min

Drug news

MHLW (Japan) grants full approval for Xocova ( ensitrelvir) to treatSARS-CoV-2 infection in Japan

Shionogi & Co., Ltd. announced that it has obtained standard approval from the Ministry of Health, Labour and Welfare (MHLW) for Xocova (Generic name: ensitrelvir fumaric acid), a novel anti-SARS-CoV-2 drug for the indication of SARS-CoV-2 infection in Japan

1 min

See all news